Entrepreneurial Spirit, Rooted in Tradition. Mitsubishi Tanabe Pharma America, Inc. (MTPA) is a U.S. subsidiary of Mitsubishi Tanabe Pharma Corporation (MTPC) in Japan, which touts a storied reputation more than 300 years in the making. Our parent company - one of Japan’s most respected - is a research-driven pharmaceutical company that has tirelessly pursued medical breakthroughs with global reach. MTPC has discovered and produced several first-in-class medicines for serious diseases, including multiple sclerosis (MS), diabetes mellitus (DM), and amyotrophic lateral sclerosis (ALS) and Parkinson's (PD).   MTPA is rapidly expanding its operations across all functional areas. MTPA’s commitment to patients and their communities continues with a robust late-stage pipeline of investigational treatments for difficult-to-treat diseases and commercializing products with significant unmet medical needs in North American markets.  In the United States, MTPA launched rare diseases treatments including RADICAVA® (edaravone) injectables in 2017, EXSERVAN™ (riluzole) oral film in 2021, and RADICAVA® (edaravone) oral suspension in 2022.  The company handles research, clinical development, sales, marketing, medical affairs, and business development functions.  MTPA is dedicated to improving the treatment environment for those with debilitating diseases, researching on real-world evidence, and creating hope for all facing illness.    The Neurology Account (PD) Specialist (NAS-PD) will be responsible for meeting and/or exceeding sales goals in an assigned territory by developing, implementing, and executing an integrated territory business plan encompassing key customer targets. The incumbent will demonstrate subject matter expertise concerning scientific and clinical information for Parkinson’s and take a customer-focused approach to engage customers in clinically relevant discussion utilizing approved materials.    The NAS-PD will effectively analyze sales data to identify opportunities for business growth or areas of concern within the assigned territory.  The incumbent will be responsible for territory business planning and execution of key company initiatives.  In the execution of all duties, the NAS-PD will adhere to company guidelines and demonstrate Integrity, Respect, Bravery, Collaboration and Persistence performing all responsibilities in accordance with company policies and procedures and applicable state and federal rules and regulations.

Entrepreneurial Spirit, Rooted in Tradition. Mitsubishi Tanabe Pharma America, Inc. (MTPA) is a U.S. subsidiary of Mitsubishi Tanabe Pharma Corporation (MTPC) in Japan, which touts a storied reputation more than 300 years in the making. Our parent company - one of Japan’s most respected - is a research-driven pharmaceutical company that has tirelessly pursued medical breakthroughs with global reach. MTPC has discovered and produced several first-in-class medicines for serious diseases, including multiple sclerosis (MS), diabetes mellitus (DM), and amyotrophic lateral sclerosis (ALS) and Parkinson's (PD).   MTPA is rapidly expanding its operations across all functional areas. MTPA’s commitment to patients and their communities continues with a robust late-stage pipeline of investigational treatments for difficult-to-treat diseases and commercializing products with significant unmet medical needs in North American markets.  In the United States, MTPA launched rare diseases treatments including RADICAVA® (edaravone) injectables in 2017, EXSERVAN™ (riluzole) oral film in 2021, and RADICAVA® (edaravone) oral suspension in 2022.  The company handles research, clinical development, sales, marketing, medical affairs, and business development functions.  MTPA is dedicated to improving the treatment environment for those with debilitating diseases, researching on real-world evidence, and creating hope for all facing illness.    The Neurology Account (PD) Specialist (NAS-PD) will be responsible for meeting and/or exceeding sales goals in an assigned territory by developing, implementing, and executing an integrated territory business plan encompassing key customer targets. The incumbent will demonstrate subject matter expertise concerning scientific and clinical information for Parkinson’s and take a customer-focused approach to engage customers in clinically relevant discussion utilizing approved materials.    The NAS-PD will effectively analyze sales data to identify opportunities for business growth or areas of concern within the assigned territory.  The incumbent will be responsible for territory business planning and execution of key company initiatives.  In the execution of all duties, the NAS-PD will adhere to company guidelines and demonstrate Integrity, Respect, Bravery, Collaboration and Persistence performing all responsibilities in accordance with company policies and procedures and applicable state and federal rules and regulations.

Entrepreneurial Spirit, Rooted in Tradition. Mitsubishi Tanabe Pharma America, Inc. (MTPA) is a U.S. subsidiary of Mitsubishi Tanabe Pharma Corporation (MTPC) in Japan, which touts a storied reputation more than 300 years in the making. Our parent company - one of Japan’s most respected - is a research-driven pharmaceutical company that has tirelessly pursued medical breakthroughs with global reach. MTPC has discovered and produced several first-in-class medicines for serious diseases, including multiple sclerosis (MS), diabetes mellitus (DM), and amyotrophic lateral sclerosis (ALS) and Parkinson's (PD).   MTPA is rapidly expanding its operations across all functional areas. MTPA’s commitment to patients and their communities continues with a robust late-stage pipeline of investigational treatments for difficult-to-treat diseases and commercializing products with significant unmet medical needs in North American markets.  In the United States, MTPA launched rare diseases treatments including RADICAVA® (edaravone) injectables in 2017, EXSERVAN™ (riluzole) oral film in 2021, and RADICAVA® (edaravone) oral suspension in 2022.  The company handles research, clinical development, sales, marketing, medical affairs, and business development functions.  MTPA is dedicated to improving the treatment environment for those with debilitating diseases, researching on real-world evidence, and creating hope for all facing illness.    The Neurology Account (PD) Specialist (NAS-PD) will be responsible for meeting and/or exceeding sales goals in an assigned territory by developing, implementing, and executing an integrated territory business plan encompassing key customer targets. The incumbent will demonstrate subject matter expertise concerning scientific and clinical information for Parkinson’s and take a customer-focused approach to engage customers in clinically relevant discussion utilizing approved materials.    The NAS-PD will effectively analyze sales data to identify opportunities for business growth or areas of concern within the assigned territory.  The incumbent will be responsible for territory business planning and execution of key company initiatives.  In the execution of all duties, the NAS-PD will adhere to company guidelines and demonstrate Integrity, Respect, Bravery, Collaboration and Persistence performing all responsibilities in accordance with company policies and procedures and applicable state and federal rules and regulations.

Entrepreneurial Spirit, Rooted in Tradition. Mitsubishi Tanabe Pharma America, Inc. (MTPA) is a U.S. subsidiary of Mitsubishi Tanabe Pharma Corporation (MTPC) in Japan, which touts a storied reputation more than 300 years in the making. Our parent company - one of Japan’s most respected - is a research-driven pharmaceutical company that has tirelessly pursued medical breakthroughs with global reach. MTPC has discovered and produced several first-in-class medicines for serious diseases, including multiple sclerosis (MS), diabetes mellitus (DM), and amyotrophic lateral sclerosis (ALS) and Parkinson's (PD).   MTPA is rapidly expanding its operations across all functional areas. MTPA’s commitment to patients and their communities continues with a robust late-stage pipeline of investigational treatments for difficult-to-treat diseases and commercializing products with significant unmet medical needs in North American markets.  In the United States, MTPA launched rare diseases treatments including RADICAVA® (edaravone) injectables in 2017, EXSERVAN™ (riluzole) oral film in 2021, and RADICAVA® (edaravone) oral suspension in 2022.  The company handles research, clinical development, sales, marketing, medical affairs, and business development functions.  MTPA is dedicated to improving the treatment environment for those with debilitating diseases, researching on real-world evidence, and creating hope for all facing illness.    The Neurology Account (PD) Specialist (NAS-PD) will be responsible for meeting and/or exceeding sales goals in an assigned territory by developing, implementing, and executing an integrated territory business plan encompassing key customer targets. The incumbent will demonstrate subject matter expertise concerning scientific and clinical information for Parkinson’s and take a customer-focused approach to engage customers in clinically relevant discussion utilizing approved materials.    The NAS-PD will effectively analyze sales data to identify opportunities for business growth or areas of concern within the assigned territory.  The incumbent will be responsible for territory business planning and execution of key company initiatives.  In the execution of all duties, the NAS-PD will adhere to company guidelines and demonstrate Integrity, Respect, Bravery, Collaboration and Persistence performing all responsibilities in accordance with company policies and procedures and applicable state and federal rules and regulations.

Entrepreneurial Spirit, Rooted in Tradition. Mitsubishi Tanabe Pharma America, Inc. (MTPA) is a U.S. subsidiary of Mitsubishi Tanabe Pharma Corporation (MTPC) in Japan, which touts a storied reputation more than 300 years in the making. Our parent company - one of Japan’s most respected - is a research-driven pharmaceutical company that has tirelessly pursued medical breakthroughs with global reach. MTPC has discovered and produced several first-in-class medicines for serious diseases, including multiple sclerosis (MS), diabetes mellitus (DM), and amyotrophic lateral sclerosis (ALS) and Parkinson's (PD).   MTPA is rapidly expanding its operations across all functional areas. MTPA’s commitment to patients and their communities continues with a robust late-stage pipeline of investigational treatments for difficult-to-treat diseases and commercializing products with significant unmet medical needs in North American markets.  In the United States, MTPA launched rare diseases treatments including RADICAVA® (edaravone) injectables in 2017, EXSERVAN™ (riluzole) oral film in 2021, and RADICAVA® (edaravone) oral suspension in 2022.  The company handles research, clinical development, sales, marketing, medical affairs, and business development functions.  MTPA is dedicated to improving the treatment environment for those with debilitating diseases, researching on real-world evidence, and creating hope for all facing illness.    The Neurology Account (PD) Specialist (NAS-PD) will be responsible for meeting and/or exceeding sales goals in an assigned territory by developing, implementing, and executing an integrated territory business plan encompassing key customer targets. The incumbent will demonstrate subject matter expertise concerning scientific and clinical information for Parkinson’s and take a customer-focused approach to engage customers in clinically relevant discussion utilizing approved materials.    The NAS-PD will effectively analyze sales data to identify opportunities for business growth or areas of concern within the assigned territory.  The incumbent will be responsible for territory business planning and execution of key company initiatives.  In the execution of all duties, the NAS-PD will adhere to company guidelines and demonstrate Integrity, Respect, Bravery, Collaboration and Persistence performing all responsibilities in accordance with company policies and procedures and applicable state and federal rules and regulations.

Entrepreneurial Spirit, Rooted in Tradition. Mitsubishi Tanabe Pharma America, Inc. (MTPA) is a U.S. subsidiary of Mitsubishi Tanabe Pharma Corporation (MTPC) in Japan, which touts a storied reputation more than 300 years in the making. Our parent company - one of Japan’s most respected - is a research-driven pharmaceutical company that has tirelessly pursued medical breakthroughs with global reach. MTPC has discovered and produced several first-in-class medicines for serious diseases, including multiple sclerosis (MS), diabetes mellitus (DM), and amyotrophic lateral sclerosis (ALS) and Parkinson's (PD).   MTPA is rapidly expanding its operations across all functional areas. MTPA’s commitment to patients and their communities continues with a robust late-stage pipeline of investigational treatments for difficult-to-treat diseases and commercializing products with significant unmet medical needs in North American markets.  In the United States, MTPA launched rare diseases treatments including RADICAVA® (edaravone) injectables in 2017, EXSERVAN™ (riluzole) oral film in 2021, and RADICAVA® (edaravone) oral suspension in 2022.  The company handles research, clinical development, sales, marketing, medical affairs, and business development functions.  MTPA is dedicated to improving the treatment environment for those with debilitating diseases, researching on real-world evidence, and creating hope for all facing illness.    The Neurology Account (PD) Specialist (NAS-PD) will be responsible for meeting and/or exceeding sales goals in an assigned territory by developing, implementing, and executing an integrated territory business plan encompassing key customer targets. The incumbent will demonstrate subject matter expertise concerning scientific and clinical information for Parkinson’s and take a customer-focused approach to engage customers in clinically relevant discussion utilizing approved materials.    The NAS-PD will effectively analyze sales data to identify opportunities for business growth or areas of concern within the assigned territory.  The incumbent will be responsible for territory business planning and execution of key company initiatives.  In the execution of all duties, the NAS-PD will adhere to company guidelines and demonstrate Integrity, Respect, Bravery, Collaboration and Persistence performing all responsibilities in accordance with company policies and procedures and applicable state and federal rules and regulations.

Entrepreneurial Spirit, Rooted in Tradition. Mitsubishi Tanabe Pharma America, Inc. (MTPA) is a U.S. subsidiary of Mitsubishi Tanabe Pharma Corporation (MTPC) in Japan, which touts a storied reputation more than 300 years in the making. Our parent company - one of Japan’s most respected - is a research-driven pharmaceutical company that has tirelessly pursued medical breakthroughs with global reach. MTPC has discovered and produced several first-in-class medicines for serious diseases, including multiple sclerosis (MS), diabetes mellitus (DM), and amyotrophic lateral sclerosis (ALS) and Parkinson's (PD).   MTPA is rapidly expanding its operations across all functional areas. MTPA’s commitment to patients and their communities continues with a robust late-stage pipeline of investigational treatments for difficult-to-treat diseases and commercializing products with significant unmet medical needs in North American markets.  In the United States, MTPA launched rare diseases treatments including RADICAVA® (edaravone) injectables in 2017, EXSERVAN™ (riluzole) oral film in 2021, and RADICAVA® (edaravone) oral suspension in 2022.  The company handles research, clinical development, sales, marketing, medical affairs, and business development functions.  MTPA is dedicated to improving the treatment environment for those with debilitating diseases, researching on real-world evidence, and creating hope for all facing illness.    The Neurology Account (PD) Specialist (NAS-PD) will be responsible for meeting and/or exceeding sales goals in an assigned territory by developing, implementing, and executing an integrated territory business plan encompassing key customer targets. The incumbent will demonstrate subject matter expertise concerning scientific and clinical information for Parkinson’s and take a customer-focused approach to engage customers in clinically relevant discussion utilizing approved materials.    The NAS-PD will effectively analyze sales data to identify opportunities for business growth or areas of concern within the assigned territory.  The incumbent will be responsible for territory business planning and execution of key company initiatives.  In the execution of all duties, the NAS-PD will adhere to company guidelines and demonstrate Integrity, Respect, Bravery, Collaboration and Persistence performing all responsibilities in accordance with company policies and procedures and applicable state and federal rules and regulations.

Entrepreneurial Spirit, Rooted in Tradition. Mitsubishi Tanabe Pharma America, Inc. (MTPA) is a U.S. subsidiary of Mitsubishi Tanabe Pharma Corporation (MTPC) in Japan, which touts a storied reputation more than 300 years in the making. Our parent company - one of Japan’s most respected - is a research-driven pharmaceutical company that has tirelessly pursued medical breakthroughs with global reach. MTPC has discovered and produced several first-in-class medicines for serious diseases, including multiple sclerosis (MS), diabetes mellitus (DM), and amyotrophic lateral sclerosis (ALS) and Parkinson's (PD).   MTPA is rapidly expanding its operations across all functional areas. MTPA’s commitment to patients and their communities continues with a robust late-stage pipeline of investigational treatments for difficult-to-treat diseases and commercializing products with significant unmet medical needs in North American markets.  In the United States, MTPA launched rare diseases treatments including RADICAVA® (edaravone) injectables in 2017, EXSERVAN™ (riluzole) oral film in 2021, and RADICAVA® (edaravone) oral suspension in 2022.  The company handles research, clinical development, sales, marketing, medical affairs, and business development functions.  MTPA is dedicated to improving the treatment environment for those with debilitating diseases, researching on real-world evidence, and creating hope for all facing illness.    The Neurology Account (PD) Specialist (NAS-PD) will be responsible for meeting and/or exceeding sales goals in an assigned territory by developing, implementing, and executing an integrated territory business plan encompassing key customer targets. The incumbent will demonstrate subject matter expertise concerning scientific and clinical information for Parkinson’s and take a customer-focused approach to engage customers in clinically relevant discussion utilizing approved materials.    The NAS-PD will effectively analyze sales data to identify opportunities for business growth or areas of concern within the assigned territory.  The incumbent will be responsible for territory business planning and execution of key company initiatives.  In the execution of all duties, the NAS-PD will adhere to company guidelines and demonstrate Integrity, Respect, Bravery, Collaboration and Persistence performing all responsibilities in accordance with company policies and procedures and applicable state and federal rules and regulations.

Entrepreneurial Spirit, Rooted in Tradition. Mitsubishi Tanabe Pharma America, Inc. (MTPA) is a U.S. subsidiary of Mitsubishi Tanabe Pharma Corporation (MTPC) in Japan, which touts a storied reputation more than 300 years in the making. Our parent company - one of Japan’s most respected - is a research-driven pharmaceutical company that has tirelessly pursued medical breakthroughs with global reach. MTPC has discovered and produced several first-in-class medicines for serious diseases, including multiple sclerosis (MS), diabetes mellitus (DM), and amyotrophic lateral sclerosis (ALS) and Parkinson's (PD).   MTPA is rapidly expanding its operations across all functional areas. MTPA’s commitment to patients and their communities continues with a robust late-stage pipeline of investigational treatments for difficult-to-treat diseases and commercializing products with significant unmet medical needs in North American markets.  In the United States, MTPA launched rare diseases treatments including RADICAVA® (edaravone) injectables in 2017, EXSERVAN™ (riluzole) oral film in 2021, and RADICAVA® (edaravone) oral suspension in 2022.  The company handles research, clinical development, sales, marketing, medical affairs, and business development functions.  MTPA is dedicated to improving the treatment environment for those with debilitating diseases, researching on real-world evidence, and creating hope for all facing illness.    The Neurology Account (PD) Specialist (NAS-PD) will be responsible for meeting and/or exceeding sales goals in an assigned territory by developing, implementing, and executing an integrated territory business plan encompassing key customer targets. The incumbent will demonstrate subject matter expertise concerning scientific and clinical information for Parkinson’s and take a customer-focused approach to engage customers in clinically relevant discussion utilizing approved materials.    The NAS-PD will effectively analyze sales data to identify opportunities for business growth or areas of concern within the assigned territory.  The incumbent will be responsible for territory business planning and execution of key company initiatives.  In the execution of all duties, the NAS-PD will adhere to company guidelines and demonstrate Integrity, Respect, Bravery, Collaboration and Persistence performing all responsibilities in accordance with company policies and procedures and applicable state and federal rules and regulations.

Entrepreneurial Spirit, Rooted in Tradition. Mitsubishi Tanabe Pharma America, Inc. (MTPA) is a U.S. subsidiary of Mitsubishi Tanabe Pharma Corporation (MTPC) in Japan, which touts a storied reputation more than 300 years in the making. Our parent company - one of Japan’s most respected - is a research-driven pharmaceutical company that has tirelessly pursued medical breakthroughs with global reach. MTPC has discovered and produced several first-in-class medicines for serious diseases, including multiple sclerosis (MS), diabetes mellitus (DM), and amyotrophic lateral sclerosis (ALS) and Parkinson's (PD).   MTPA is rapidly expanding its operations across all functional areas. MTPA’s commitment to patients and their communities continues with a robust late-stage pipeline of investigational treatments for difficult-to-treat diseases and commercializing products with significant unmet medical needs in North American markets.  In the United States, MTPA launched rare diseases treatments including RADICAVA® (edaravone) injectables in 2017, EXSERVAN™ (riluzole) oral film in 2021, and RADICAVA® (edaravone) oral suspension in 2022.  The company handles research, clinical development, sales, marketing, medical affairs, and business development functions.  MTPA is dedicated to improving the treatment environment for those with debilitating diseases, researching on real-world evidence, and creating hope for all facing illness.    The Neurology Account (PD) Specialist (NAS-PD) will be responsible for meeting and/or exceeding sales goals in an assigned territory by developing, implementing, and executing an integrated territory business plan encompassing key customer targets. The incumbent will demonstrate subject matter expertise concerning scientific and clinical information for Parkinson’s and take a customer-focused approach to engage customers in clinically relevant discussion utilizing approved materials.    The NAS-PD will effectively analyze sales data to identify opportunities for business growth or areas of concern within the assigned territory.  The incumbent will be responsible for territory business planning and execution of key company initiatives.  In the execution of all duties, the NAS-PD will adhere to company guidelines and demonstrate Integrity, Respect, Bravery, Collaboration and Persistence performing all responsibilities in accordance with company policies and procedures and applicable state and federal rules and regulations.

Entrepreneurial Spirit, Rooted in Tradition. Mitsubishi Tanabe Pharma America, Inc. (MTPA) is a U.S. subsidiary of Mitsubishi Tanabe Pharma Corporation (MTPC) in Japan, which touts a storied reputation more than 300 years in the making. Our parent company - one of Japan’s most respected - is a research-driven pharmaceutical company that has tirelessly pursued medical breakthroughs with global reach. MTPC has discovered and produced several first-in-class medicines for serious diseases, including multiple sclerosis (MS), diabetes mellitus (DM), and amyotrophic lateral sclerosis (ALS) and Parkinson's (PD).   MTPA is rapidly expanding its operations across all functional areas. MTPA’s commitment to patients and their communities continues with a robust late-stage pipeline of investigational treatments for difficult-to-treat diseases and commercializing products with significant unmet medical needs in North American markets.  In the United States, MTPA launched rare diseases treatments including RADICAVA® (edaravone) injectables in 2017, EXSERVAN™ (riluzole) oral film in 2021, and RADICAVA® (edaravone) oral suspension in 2022.  The company handles research, clinical development, sales, marketing, medical affairs, and business development functions.  MTPA is dedicated to improving the treatment environment for those with debilitating diseases, researching on real-world evidence, and creating hope for all facing illness.    The Neurology Account (PD) Specialist (NAS-PD) will be responsible for meeting and/or exceeding sales goals in an assigned territory by developing, implementing, and executing an integrated territory business plan encompassing key customer targets. The incumbent will demonstrate subject matter expertise concerning scientific and clinical information for Parkinson’s and take a customer-focused approach to engage customers in clinically relevant discussion utilizing approved materials.    The NAS-PD will effectively analyze sales data to identify opportunities for business growth or areas of concern within the assigned territory.  The incumbent will be responsible for territory business planning and execution of key company initiatives.  In the execution of all duties, the NAS-PD will adhere to company guidelines and demonstrate Integrity, Respect, Bravery, Collaboration and Persistence performing all responsibilities in accordance with company policies and procedures and applicable state and federal rules and regulations.

Entrepreneurial Spirit, Rooted in Tradition. Mitsubishi Tanabe Pharma America, Inc. (MTPA) is a U.S. subsidiary of Mitsubishi Tanabe Pharma Corporation (MTPC) in Japan, which touts a storied reputation more than 300 years in the making. Our parent company - one of Japan’s most respected - is a research-driven pharmaceutical company that has tirelessly pursued medical breakthroughs with global reach. MTPC has discovered and produced several first-in-class medicines for serious diseases, including multiple sclerosis (MS), diabetes mellitus (DM), and amyotrophic lateral sclerosis (ALS) and Parkinson's (PD).   MTPA is rapidly expanding its operations across all functional areas. MTPA’s commitment to patients and their communities continues with a robust late-stage pipeline of investigational treatments for difficult-to-treat diseases and commercializing products with significant unmet medical needs in North American markets.  In the United States, MTPA launched rare diseases treatments including RADICAVA® (edaravone) injectables in 2017, EXSERVAN™ (riluzole) oral film in 2021, and RADICAVA® (edaravone) oral suspension in 2022.  The company handles research, clinical development, sales, marketing, medical affairs, and business development functions.  MTPA is dedicated to improving the treatment environment for those with debilitating diseases, researching on real-world evidence, and creating hope for all facing illness.    The Neurology Account (PD) Specialist (NAS-PD) will be responsible for meeting and/or exceeding sales goals in an assigned territory by developing, implementing, and executing an integrated territory business plan encompassing key customer targets. The incumbent will demonstrate subject matter expertise concerning scientific and clinical information for Parkinson’s and take a customer-focused approach to engage customers in clinically relevant discussion utilizing approved materials.    The NAS-PD will effectively analyze sales data to identify opportunities for business growth or areas of concern within the assigned territory.  The incumbent will be responsible for territory business planning and execution of key company initiatives.  In the execution of all duties, the NAS-PD will adhere to company guidelines and demonstrate Integrity, Respect, Bravery, Collaboration and Persistence performing all responsibilities in accordance with company policies and procedures and applicable state and federal rules and regulations.

Entrepreneurial Spirit, Rooted in Tradition. Mitsubishi Tanabe Pharma America, Inc. (MTPA) is a U.S. subsidiary of Mitsubishi Tanabe Pharma Corporation (MTPC) in Japan, which touts a storied reputation more than 300 years in the making. Our parent company - one of Japan’s most respected - is a research-driven pharmaceutical company that has tirelessly pursued medical breakthroughs with global reach. MTPC has discovered and produced several first-in-class medicines for serious diseases, including multiple sclerosis (MS), diabetes mellitus (DM), and amyotrophic lateral sclerosis (ALS) and Parkinson's (PD).   MTPA is rapidly expanding its operations across all functional areas. MTPA’s commitment to patients and their communities continues with a robust late-stage pipeline of investigational treatments for difficult-to-treat diseases and commercializing products with significant unmet medical needs in North American markets.  In the United States, MTPA launched rare diseases treatments including RADICAVA® (edaravone) injectables in 2017, EXSERVAN™ (riluzole) oral film in 2021, and RADICAVA® (edaravone) oral suspension in 2022.  The company handles research, clinical development, sales, marketing, medical affairs, and business development functions.  MTPA is dedicated to improving the treatment environment for those with debilitating diseases, researching on real-world evidence, and creating hope for all facing illness.    The Neurology Account (PD) Specialist (NAS-PD) will be responsible for meeting and/or exceeding sales goals in an assigned territory by developing, implementing, and executing an integrated territory business plan encompassing key customer targets. The incumbent will demonstrate subject matter expertise concerning scientific and clinical information for Parkinson’s and take a customer-focused approach to engage customers in clinically relevant discussion utilizing approved materials.    The NAS-PD will effectively analyze sales data to identify opportunities for business growth or areas of concern within the assigned territory.  The incumbent will be responsible for territory business planning and execution of key company initiatives.  In the execution of all duties, the NAS-PD will adhere to company guidelines and demonstrate Integrity, Respect, Bravery, Collaboration and Persistence performing all responsibilities in accordance with company policies and procedures and applicable state and federal rules and regulations.

Entrepreneurial Spirit, Rooted in Tradition. Mitsubishi Tanabe Pharma America, Inc. (MTPA) is a U.S. subsidiary of Mitsubishi Tanabe Pharma Corporation (MTPC) in Japan, which touts a storied reputation more than 300 years in the making. Our parent company - one of Japan’s most respected - is a research-driven pharmaceutical company that has tirelessly pursued medical breakthroughs with global reach. MTPC has discovered and produced several first-in-class medicines for serious diseases, including multiple sclerosis (MS), diabetes mellitus (DM), and amyotrophic lateral sclerosis (ALS) and Parkinson's (PD).   MTPA is rapidly expanding its operations across all functional areas. MTPA’s commitment to patients and their communities continues with a robust late-stage pipeline of investigational treatments for difficult-to-treat diseases and commercializing products with significant unmet medical needs in North American markets.  In the United States, MTPA launched rare diseases treatments including RADICAVA® (edaravone) injectables in 2017, EXSERVAN™ (riluzole) oral film in 2021, and RADICAVA® (edaravone) oral suspension in 2022.  The company handles research, clinical development, sales, marketing, medical affairs, and business development functions.  MTPA is dedicated to improving the treatment environment for those with debilitating diseases, researching on real-world evidence, and creating hope for all facing illness.    The Neurology Account (PD) Specialist (NAS-PD) will be responsible for meeting and/or exceeding sales goals in an assigned territory by developing, implementing, and executing an integrated territory business plan encompassing key customer targets. The incumbent will demonstrate subject matter expertise concerning scientific and clinical information for Parkinson’s and take a customer-focused approach to engage customers in clinically relevant discussion utilizing approved materials.    The NAS-PD will effectively analyze sales data to identify opportunities for business growth or areas of concern within the assigned territory.  The incumbent will be responsible for territory business planning and execution of key company initiatives.  In the execution of all duties, the NAS-PD will adhere to company guidelines and demonstrate Integrity, Respect, Bravery, Collaboration and Persistence performing all responsibilities in accordance with company policies and procedures and applicable state and federal rules and regulations.

Entrepreneurial Spirit, Rooted in Tradition. Mitsubishi Tanabe Pharma America, Inc. (MTPA) is a U.S. subsidiary of Mitsubishi Tanabe Pharma Corporation (MTPC) in Japan, which touts a storied reputation more than 300 years in the making. Our parent company - one of Japan’s most respected - is a research-driven pharmaceutical company that has tirelessly pursued medical breakthroughs with global reach. MTPC has discovered and produced several first-in-class medicines for serious diseases, including multiple sclerosis (MS), diabetes mellitus (DM), and amyotrophic lateral sclerosis (ALS) and Parkinson's (PD).   MTPA is rapidly expanding its operations across all functional areas. MTPA’s commitment to patients and their communities continues with a robust late-stage pipeline of investigational treatments for difficult-to-treat diseases and commercializing products with significant unmet medical needs in North American markets.  In the United States, MTPA launched rare diseases treatments including RADICAVA® (edaravone) injectables in 2017, EXSERVAN™ (riluzole) oral film in 2021, and RADICAVA® (edaravone) oral suspension in 2022.  The company handles research, clinical development, sales, marketing, medical affairs, and business development functions.  MTPA is dedicated to improving the treatment environment for those with debilitating diseases, researching on real-world evidence, and creating hope for all facing illness.    The Neurology Account (PD) Specialist (NAS-PD) will be responsible for meeting and/or exceeding sales goals in an assigned territory by developing, implementing, and executing an integrated territory business plan encompassing key customer targets. The incumbent will demonstrate subject matter expertise concerning scientific and clinical information for Parkinson’s and take a customer-focused approach to engage customers in clinically relevant discussion utilizing approved materials.    The NAS-PD will effectively analyze sales data to identify opportunities for business growth or areas of concern within the assigned territory.  The incumbent will be responsible for territory business planning and execution of key company initiatives.  In the execution of all duties, the NAS-PD will adhere to company guidelines and demonstrate Integrity, Respect, Bravery, Collaboration and Persistence performing all responsibilities in accordance with company policies and procedures and applicable state and federal rules and regulations.

Entrepreneurial Spirit, Rooted in Tradition. Mitsubishi Tanabe Pharma America, Inc. (MTPA) is a U.S. subsidiary of Mitsubishi Tanabe Pharma Corporation (MTPC) in Japan, which touts a storied reputation more than 300 years in the making. Our parent company - one of Japan’s most respected - is a research-driven pharmaceutical company that has tirelessly pursued medical breakthroughs with global reach. MTPC has discovered and produced several first-in-class medicines for serious diseases, including multiple sclerosis (MS), diabetes mellitus (DM), and amyotrophic lateral sclerosis (ALS) and Parkinson's (PD).   MTPA is rapidly expanding its operations across all functional areas. MTPA’s commitment to patients and their communities continues with a robust late-stage pipeline of investigational treatments for difficult-to-treat diseases and commercializing products with significant unmet medical needs in North American markets.  In the United States, MTPA launched rare diseases treatments including RADICAVA® (edaravone) injectables in 2017, EXSERVAN™ (riluzole) oral film in 2021, and RADICAVA® (edaravone) oral suspension in 2022.  The company handles research, clinical development, sales, marketing, medical affairs, and business development functions.  MTPA is dedicated to improving the treatment environment for those with debilitating diseases, researching on real-world evidence, and creating hope for all facing illness.    The Neurology Account (PD) Specialist (NAS-PD) will be responsible for meeting and/or exceeding sales goals in an assigned territory by developing, implementing, and executing an integrated territory business plan encompassing key customer targets. The incumbent will demonstrate subject matter expertise concerning scientific and clinical information for Parkinson’s and take a customer-focused approach to engage customers in clinically relevant discussion utilizing approved materials.    The NAS-PD will effectively analyze sales data to identify opportunities for business growth or areas of concern within the assigned territory.  The incumbent will be responsible for territory business planning and execution of key company initiatives.  In the execution of all duties, the NAS-PD will adhere to company guidelines and demonstrate Integrity, Respect, Bravery, Collaboration and Persistence performing all responsibilities in accordance with company policies and procedures and applicable state and federal rules and regulations.

Entrepreneurial Spirit, Rooted in Tradition. Mitsubishi Tanabe Pharma America, Inc. (MTPA) is a U.S. subsidiary of Mitsubishi Tanabe Pharma Corporation (MTPC) in Japan, which touts a storied reputation more than 300 years in the making. Our parent company - one of Japan’s most respected - is a research-driven pharmaceutical company that has tirelessly pursued medical breakthroughs with global reach. MTPC has discovered and produced several first-in-class medicines for serious diseases, including multiple sclerosis (MS), diabetes mellitus (DM), and amyotrophic lateral sclerosis (ALS).   MTPA is rapidly expanding its operations across all functional areas. MTPA’s commitment to patients and their communities continues with a robust late-stage pipeline of investigational treatments for difficult-to-treat diseases and commercializing products with significant unmet medical needs in North American markets.  In the United States, MTPA launched rare diseases treatments including RADICAVA® (edaravone) injectables in 2017, EXSERVAN™ (riluzole) oral film in 2021, and RADICAVA® (edaravone) oral suspension in 2022.  The company handles research, clinical development, sales, marketing, medical affairs, and business development functions.  MTPA is dedicated to improving the treatment environment for those with debilitating diseases, researching on real-world evidence, and creating hope for all facing illness.    The Associate Director, Business Development will seek out potential business opportunities through strong networking with other pharmaceutical and biotechnology companies, scientific organizations, academia, and related parties as well as searching available databases.   The incumbent will evaluate opportunities primarily from a scientific and strategic point of view, then support further evaluation by the due diligence team efficiently communicating with excellent facilitation. The incumbent will also lead initial partnership, licensing and/or acquisition negotiations with sufficient knowledge regarding transactions in pharmaceutical business, as well as with sufficient understanding about finance and accounting, and legal perspective.

Entrepreneurial Spirit, Rooted in Tradition. Mitsubishi Tanabe Pharma America, Inc. (MTPA) is a U.S. subsidiary of Mitsubishi Tanabe Pharma Corporation (MTPC) in Japan, which touts a storied reputation more than 300 years in the making. Our parent company - one of Japan’s most respected - is a research-driven pharmaceutical company that has tirelessly pursued medical breakthroughs with global reach. MTPC has discovered and produced several first-in-class medicines for serious diseases, including multiple sclerosis (MS), diabetes mellitus (DM), and amyotrophic lateral sclerosis (ALS).   MTPA is rapidly expanding its operations across all functional areas. MTPA’s commitment to patients and their communities continues with a robust late-stage pipeline of investigational treatments for difficult-to-treat diseases and commercializing products with significant unmet medical needs in North American markets.  In the United States, MTPA launched rare diseases treatments including RADICAVA® (edaravone) injectables in 2017, EXSERVAN™ (riluzole) oral film in 2021, and RADICAVA® (edaravone) oral suspension in 2022.  The company handles research, clinical development, sales, marketing, medical affairs, and business development functions.  MTPA is dedicated to improving the treatment environment for those with debilitating diseases, researching on real-world evidence, and creating hope for all facing illness.    The Executive Director, Data Management and Medical Writing is a leadership role responsible for overseeing the Data Science and Medical Writing organization, and for the development and ongoing operation of the company's tools, technologies, and technical solutions leveraging data science, advanced analytics, machine learning and other algorithms to support clinical development activities.   The Executive Director, Data Management and Medical Writing draws on industry expertise to serve as a key contributor to strategic planning. This is realized through membership on the Global Clinical Development Leadership Team.

Entrepreneurial Spirit, Rooted in Tradition. Mitsubishi Tanabe Pharma America, Inc. (MTPA) is a U.S. subsidiary of Mitsubishi Tanabe Pharma Corporation (MTPC) in Japan, which touts a storied reputation more than 300 years in the making. Our parent company - one of Japan’s most respected - is a research-driven pharmaceutical company that has tirelessly pursued medical breakthroughs with global reach. MTPC has discovered and produced several first-in-class medicines for serious diseases, including multiple sclerosis (MS), diabetes mellitus (DM), and amyotrophic lateral sclerosis (ALS).   MTPA is rapidly expanding its operations across all functional areas. MTPA’s commitment to patients and their communities continues with a robust late-stage pipeline of investigational treatments for difficult-to-treat diseases and commercializing products with significant unmet medical needs in North American markets.  In the United States, MTPA launched rare diseases treatments including RADICAVA® (edaravone) injectables in 2017, EXSERVAN™ (riluzole) oral film in 2021, and RADICAVA® (edaravone) oral suspension in 2022.  The company handles research, clinical development, sales, marketing, medical affairs, and business development functions.  MTPA is dedicated to improving the treatment environment for those with debilitating diseases, researching on real-world evidence, and creating hope for all facing illness.    Provides administrative support for assigned individual(s) and/or department(s).

Entrepreneurial Spirit, Rooted in Tradition. Mitsubishi Tanabe Pharma America, Inc. (MTPA) is a U.S. subsidiary of Mitsubishi Tanabe Pharma Corporation (MTPC) in Japan, which touts a storied reputation more than 300 years in the making. Our parent company - one of Japan’s most respected - is a research-driven pharmaceutical company that has tirelessly pursued medical breakthroughs with global reach. MTPC has discovered and produced several first-in-class medicines for serious diseases, including multiple sclerosis (MS), diabetes mellitus (DM), and amyotrophic lateral sclerosis (ALS).   MTPA is rapidly expanding its operations across all functional areas. MTPA’s commitment to patients and their communities continues with a robust late-stage pipeline of investigational treatments for difficult-to-treat diseases and commercializing products with significant unmet medical needs in North American markets.  In the United States, MTPA launched rare diseases treatments including RADICAVA® (edaravone) injectables in 2017, EXSERVAN™ (riluzole) oral film in 2021, and RADICAVA® (edaravone) oral suspension in 2022.  The company handles research, clinical development, sales, marketing, medical affairs, and business development functions.  MTPA is dedicated to improving the treatment environment for those with debilitating diseases, researching on real-world evidence, and creating hope for all facing illness.    The Neurology Account Specialist (NAS) will be responsible for meeting and/or exceeding sales goals in an assigned territory by developing, implementing, and executing an integrated territory business plan encompassing key customer targets. The incumbent will demonstrate subject matter expertise concerning scientific and clinical information for ALS and take a customer-focused approach to engage customers in clinically relevant discussion utilizing approved materials.    The NAS will effectively analyze sales data to identify opportunities for business growth or areas of concern within the assigned territory.  The incumbent will be responsible for territory business planning and execution of key company initiatives.  In the execution of all duties, the NAS will adhere to company guidelines and demonstrate Integrity, Respect, Bravery, Collaboration and Persistence performing all responsibilities in accordance with company policies and procedures and applicable state and federal rules and regulations.